BioMarin begins pompe disease drug study
BioMarin Pharmaceutical has initiated a Phase 1/2 trial to evaluate BMN 701 - a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), as a treatment for Pompe disease.
The Phase 1/2 trial is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701.
In the study, BMN 701 will be administered as an intravenous infusion every two weeks at doses of 5mg/kg, 10mg/kg and 20mg/kg.
The company plans to enroll approximately 30 patients between 13 and 65 years of age, with late-onset Pompe disease for a treatment period of 24 weeks.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs